Results 31 to 40 of about 13,742 (189)

Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics

BMC Cancer, 2013
Background Changes in cell shape and plasticity in cytoskeletal dynamics are critically involved in cell adhesion, migration, invasion and the overall process of metastasis.
Brandhagen BreeAnn N, Tieszen Chelsea R, Ulmer Tara M, Tracy Maria S, Goyeneche Alicia A, Telleria Carlos M   +5 more
doaj   +1 more source

A single-day treatment with mifepristone is sufficient to normalize chronic glucocorticoid induced suppression of hippocampal cell proliferation. [PDF]

PLoS ONE, 2012
BACKGROUND: Chronic stress or prolonged administration of glucocorticoids suppresses proliferation and/or survival of newborn cells in adult rat dentate gyrus.
Pu Hu, Charlotte Oomen, Anne-Marie van Dam, Jordi Wester, Jiang-Ning Zhou, Marian Joëls, Paul J Lucassen   +6 more
doaj   +1 more source

Demographic Factors Influencing Eligibility for EMA in South Australia

Australian and New Zealand Journal of Obstetrics and Gynaecology, EarlyView.
ABSTRACT Background Early medical abortion (EMA) can be performed by administration of mifepristone and misoprostol in an outpatient setting prior to 63 days gestation in Australia. While this is a flexible, efficacious and safe option for abortion, it requires early identification of pregnancy and efficient access to a clinical service. Outpatient EMA
Laura Slade, Jennie Louise, Katina D'Onise, Jodie Dodd   +3 more
wiley   +1 more source

A prospective study on the effectiveness of a combination regime (Mifepristone and Misoprostol) in comparison with Misoprostol for missed abortion

Journal of Family Medicine and Primary Care, 2023
Introduction: Misoprostol is widely used in the medical management of missed abortions. However, pretreatment with Mifepristone has shown to be effective but still not recommended to be used in missed abortions.
Nidhi Gupta, Reva Tripathi, Sumedha Sharma, Aruna Nigam, Sanjeet Panesar   +4 more
doaj   +1 more source

The Sociodemographic Benefits of Extending MS‐2Step to 70 Days in Australia

Australian and New Zealand Journal of Obstetrics and Gynaecology, EarlyView.
ABSTRACT In many areas of the world, outpatient early medical abortion (EMA) is provided through mifepristone and misoprostol up to 10 weeks or 70 days gestation; however in Australia access is restricted to 63 days. A retrospective cohort study using South Australian data from 2012 to 2020 compares women undergoing abortion at less than 9 weeks with ...
Laura Slade, Jennie Louise, Katina D'Onise, Jodie Dodd   +3 more
wiley   +1 more source

Effects of mifepristone on adipocyte differentiation in mouse 3T3-L1 cells

Cellular & Molecular Biology Letters
Background Both glucocorticoid receptor and peroxisome proliferator-activated receptor-γ (PPARγ) play a critical role in adipocyte differentiation.
Takeshi Hashimoto, Katsuya Hirano
doaj   +1 more source

Management of early pregnancy loss by reproductive endocrinologists: does access to mifepristone matter?

F&S Reports
Objective: To describe patterns and variations in the medical and procedural management of early pregnancy loss (EPL) among reproductive endocrinology and infertility specialists, with attention to mifepristone use. Design: Cross-sectional.
Zachary S. Anderson, M.D., Richard J. Paulson, M.D., Brian T. Nguyen, M.Sc., M.D.   +2 more
doaj   +1 more source

Efficacy and Tolerability of Metyrapone in Mild Autonomous Cortisol Secretion: Real‐World Findings From Clinical Practice

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Mild autonomous cortisol secretion (MACS) is associated with increased cardiometabolic risk factors including hypertension, type 2 diabetes and dyslipidaemia. By using evening doses of metyrapone, a short‐acting 11‐β hydroxylase inhibitor, it has been shown that it is possible to reset the abnormal circadian cortisol rhythm in MACS ...
Simon Berry, Ahmed Iqbal, John Newell‐Price, Miguel Debono   +3 more
wiley   +1 more source

Medical regimens for abortion at 12 weeks and above: a systematic review and meta-analysis

Contraception: X, 2020
Background: Mifepristone and misoprostol are recommended for second-trimester medical abortion, but consensus is unclear on the ideal regimen. Objectives: The objectives were to systematically review randomized controlled trials (RCTs) investigating ...
Katherine Whitehouse, Ashley Brant, Marita Sporstol Fonhus, Antonella Lavelanet, Bela Ganatra   +4 more
doaj   +1 more source

Clinical Outcomes and Women's Experiences before and after the Introduction of Mifepristone into Second-Trimester Medical Abortion Services in South Africa. [PDF]

PLoS ONE, 2016
OBJECTIVE:To document clinical outcomes and women's experiences following the introduction of mifepristone into South African public sector second-trimester medical abortion services, and compare with historic cohorts receiving misoprostol-only.
Deborah Constant, Jane Harries, Thokozile Malaba, Landon Myer, Malika Patel, Gregory Petro, Daniel Grossman   +6 more
doaj   +1 more source